Legal Opinion
In re Effexor Antitrust Litig.
District Court, D. New Jersey
Decided September 18, 2018No. Civil Action No. 3:11-cv-5661 (PGS)(LHG)PublishedCited by 6 opinions
1Opinion of the Court
PETER G. SHERIDAN, U.S.D.J.
Presently before the Court is Defendants Wyeth Inc., Wyeth Manufacturing Limited, Wyeth Ireland Pharmaceutical Products (collectively, "Wyeth"), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals *442Industries Limited's (collectively, "Teva") Motion for Judgment on the Pleadings pursuant Federal Rule of Civil Procedure 12(c), regarding End-Payer Plaintiffs' Third Amended Consolidated Complaint. (ECF No. 165).1 This case arises from allegations that two drug companies, Wyeth and Teva, engaged in an anticompetitive scheme that prevented the generic drug of Effexor…
2Cases cited77 opinions
- Ashcroft v. IqbalSupreme Court of the United States · 2009
- Lujan v. Defenders of WildlifeSupreme Court of the United States · 1992
- Erie Railroad v. TompkinsSupreme Court of the United States · 1938
- Hanna v. PlumerSupreme Court of the United States · 1965
- DaimlerChrysler Corp. v. CunoSupreme Court of the United States · 2006
72 more not listed; retrieve them via the Exa API.
3Cited by6 opinions
- In re Generic Pharm. Pricing Antitrust Litig.District Court, E.D. Pennsylvania · 2019
- CALABRIA RISTORANTE, INC. v. RUGGIERO SEAFOOD, INC.District Court, D. New Jersey · 2023
- In Re Glumetza Antitrust LitigationDistrict Court, N.D. California · 2020
- In re Novartis and Par Antitrust LitigationDistrict Court, S.D. New York · 2019
- Rite Aid Corporation v. Novartis Pharmaceuticals Corp.District Court, S.D. New York · 2019
1 more not listed; retrieve them via the Exa API.